10x Genomics (TXG) Non-Current Deffered Revenue (2018 - 2026)

10x Genomics has disclosed Non-Current Deffered Revenue across 7 years of filings, most recently posting $9.7 million for Q2 2026.

• In Q2 2026, Non-Current Deffered Revenue fell 14.08% year-over-year to $9.7 million; the TTM figure through Jun 2026 stood at $9.7 million (down 14.08% YoY), while the FY2025 annual figure was $10.5 million, down 16.08% from the prior year.
• Non-Current Deffered Revenue came in at $9.7 million for Q2 2026 at 10x Genomics, down from $10.1 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $12.6 million in Q1 2025 to a low of $3.2 million in Q4 2022.
• Average Non-Current Deffered Revenue over 5 years is $10.3 million, with a median of $10.7 million recorded in 2025.
• Year-over-year, Non-Current Deffered Revenue jumped 178.48% in 2023 and declined 19.34% in 2026.
• Over 5 years, Non-Current Deffered Revenue stood at $3.2 million in 2022, then jumped by 178.48% to $8.8 million in 2023, then surged by 41.97% to $12.5 million in 2024, then retreated by 16.08% to $10.5 million in 2025, then slipped by 7.79% to $9.7 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $9.7 million in Q2 2026, $10.1 million in Q1 2026, and $10.5 million in Q4 2025.